- Home
- OSUR vs CRDF Comparison
OSUR vs CRDF Comparison
Compare OSUR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- CRDF
- Stock Information
- Founded
- OSUR 2000
- CRDF 1999
- Country
- OSUR United States
- CRDF United States
- Employees
- OSUR N/A
- CRDF N/A
- Industry
- OSUR Medical/Dental Instruments
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OSUR Health Care
- CRDF Health Care
- Exchange
- OSUR Nasdaq
- CRDF Nasdaq
- Market Cap
- OSUR 266.7M
- CRDF 288.7M
- IPO Year
- OSUR 1986
- CRDF N/A
- Fundamental
- Price
- OSUR $3.57
- CRDF $3.73
- Analyst Decision
- OSUR Hold
- CRDF Strong Buy
- Analyst Count
- OSUR 2
- CRDF 4
- Target Price
- OSUR $5.50
- CRDF $12.00
- AVG Volume (30 Days)
- OSUR 1.0M
- CRDF 1.2M
- Earning Date
- OSUR 05-07-2025
- CRDF 05-01-2025
- Dividend Yield
- OSUR N/A
- CRDF N/A
- EPS Growth
- OSUR N/A
- CRDF N/A
- EPS
- OSUR N/A
- CRDF N/A
- Revenue
- OSUR $185,827,000.00
- CRDF $683,000.00
- Revenue This Year
- OSUR N/A
- CRDF N/A
- Revenue Next Year
- OSUR $8.41
- CRDF N/A
- P/E Ratio
- OSUR N/A
- CRDF N/A
- Revenue Growth
- OSUR N/A
- CRDF 39.96
- 52 Week Low
- OSUR $2.69
- CRDF $2.01
- 52 Week High
- OSUR $6.38
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- OSUR 51.84
- CRDF 45.87
- Support Level
- OSUR $3.40
- CRDF $3.65
- Resistance Level
- OSUR $4.22
- CRDF $3.88
- Average True Range (ATR)
- OSUR 0.16
- CRDF 0.26
- MACD
- OSUR 0.04
- CRDF -0.02
- Stochastic Oscillator
- OSUR 41.18
- CRDF 30.00
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").